Head-to-head · Cost-Efficiency Index
eMI Aesthetics vs Ivy Rx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
eMI Aesthetics
Shoppers wanting all-50-state compounded semaglutide or tirzepatide access with an AI progress simulator, willing to accept a price range rather than a fixed quote.
Visit eMI AestheticsIvy Rx
Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms.
Visit Ivy RxThe verdict
eMI Aesthetics and Ivy Rx tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with eMI Aesthetics (ranked #99, a hair above #102) — Shoppers wanting all-50-state compounded semaglutide or tirzepatide access with an AI progress simulator, willing to accept a price range rather than a fixed quote. But Ivy Rx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs eMI Aesthetics.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | eMI Aesthetics | Ivy Rx |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $179/mo (compounded) | $97/mo (microdose tier, promotional rate, compounded) |
| Tirzepatide / mo | $269/mo (compounded) | $199/mo (brand Mounjaro, compounded) |
| Semaglutide / yr (modeled) | $2,148 | $1,164 |
| Tirzepatide / yr (modeled) | $3,228 | $2,388 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Yes |
| Rank here | #99 | #102 |
eMI Aesthetics
69/100Where the value is
- Available to eligible patients in all 50 U.S. states per the site's own GLP-1 program page
- Offers semaglutide in both injectable and oral form, plus tirzepatide, on one platform
- Full program cost is bundled — evaluation, medication, delivery, coaching, and follow-up with no separate fees itemized
The tradeoffs
- The advertised '$179/month' is the FLOOR of a $179-$249 range for the injection alone; oral semaglutide runs $209-$279 and tirzepatide $269-$339 — the actual price a patient pays isn't disclosed before intake
- No specific dispensing pharmacy is named
Ivy Rx
69/100Where the value is
- Genuinely low entry price on the semaglutide microdose tier ($77/mo)
- HSA/FSA eligible with itemized receipts for reimbursement
- Legal entity is named (Ivy RX PLLC), which many competitors in this batch do not disclose
The tradeoffs
- The standard semaglutide price is shown as a struck-through discount ('$197 $97') with no label clarifying whether $97 is a standing rate or a temporary promo
- The advertised $199/mo tirzepatide rate requires a 12-month upfront lump-sum payment, not month-to-month billing, and a separate unexplained $1,399 vial price appears on the same page
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.